Pembuka Laporan Manajemen Profil Perusahaan

Opening Management Report Company Profile

Ikhtisar Kinerja Keuangan

Financial Performance Overview

Data keuangan yang tercantum di bawah ini The financial figures listed in this discussion are
merupakan angka konsolidasian. Angka pada consolidated figures. Figures in the tables and
tabel dan grafik dalam Laporan Tahunan ini graphs in this Annual Report use Indonesian
menggunakan notasi Bahasa Indonesia. notation.

IKHTISAR POSISI KEUANGAN KONSOLIDASIAN SUMMARY OF BIO FARMA’S CONSOLIDATED

BIO FARMA FINANCIAL POSITION
Dalam Rp Juta In Rp Million

Ikhtisar Posisi Keuangan Summary of Consolidated

2021 2020 2019
Konsolidasian Financial Position

Aset Lancar 22.254.705 15.027.584 10.677.097 Current Assets

Investasi pada Entitas Asosiasi 1.215 1.116 742 Investment in Associates

Aset Tetap 15.348.795 15.285.848 15.144.400 Fixed Assets

Aset Hak Guna 471.540 422.298 - Right of Use Assets

Properti Investasi 1.073.727 1.013.636 1.011.569 Investment Properties

Aset Tak Berwujud 299.269 248.280 213.557 Intangible Assets

Aset Tidak Lancar Lainnya 66.589 298.047 311.571 Other Non-Current Assets

Total Aset 40.444.178 32.692.678 27.646.509 Total Assets

Liabilitas Jangka Pendek 16.971.393 11.863.015 8.721.734 Current Liabilities

Liabilitas Jangka Panjang 6.091.318 4.988.318 4.858.670 Non-Current Liabilities

Total Liabilitas 23.062.711 16.851.333 13.580.404 Total Liabilities

Total Ekuitas 17.381.467 15.841.345 14.066.105 Total Equity

Modal Kerja Bersih 5.283.312 3.164.569 1.955.363 Net Working Capital

IKHTISAR LAPORAN LABA RUGI KONSOLIDASI BIO FARMA CONSOLIDATED STATEMENTS OF

BIO FARMA PROFIT LOSS SUMMARY
Dalam Rp Juta In Rp Million

Ikhtisar Laporan Laba Rugi Summary of Consolidated

2021 2020 2019
Konsolidasian Income Statement

Pendapatan 43.436.967 14.327.964 13.302.302 Income

Laba Bruto 8.373.013 5.114.867 4.985.005 Gross Profit

Laba Usaha 3.308.550 828.890 883.470 Operating Profit

Laba Tahun Berjalan 1.931.289 289.185 355.940 Net Profit for the Year

Total Laba Komprehensif tahun 1.628.018 162.398 348.371 Total Comprehensive Income for the
berjalan Year

Laba yang Dapat Diatribusikan 1.920.779 284.631 355.940 Profit Attributable to Owners of the
Kepada Pemilik Entitas Induk Parent Entity

Laba yang Dapat Diatribusikan 10.509 4.554 - Profit Attributable to Non-

kepada Kepentingan Non Controlling Interests
Pengendali

Total 1.931.289 289.185 355.940 Total

44 PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report

 Analisis dan Pembahasan Manajemen atas Kinerja Perusahaan Tata Kelola Perusahaan
Management Discussion and Analysis regarding the Company’s Performance Good Corporate Governance

RASIO-RASIO KEUANGAN, RENTABILITAS DAN Financial Ratios, Rentability, and Ability

KEMAMPUAN MEMBAYAR HUTANG to Pay Debt

YTD YTD YTD

Desember Desember Desember %
December December December

Rasio Keuangan Realisasi Realisasi Consolidated Financial

Konsolidasi Budget Ratios
Realisation Realisation
2021
2020 2021 2:3 2:1

(1) (2) (3)

EBITDA (Rp Miliar) 1.314,99 4.027,39 2.693,37 149,53% 306,27% EBITDA (Rp Billion)

CFO (Rp Miliar) 19,17 6.596,76 1.828,98 360,68% 34407,42% CFO (Rp Billion)

Interest Bearing DEBT Interest Bearing DEBT

(Rp Miliar) 11.281,57 8.705,81 8.728,16 99,74% 77,17% (Rp Miliar)

Debt/EBITDA (Kali) 8,58 2,16 3,24 66,71% 25,20% Debt/EBITDA (Kali)

Debt to Equity (%) 71,22% 50,09% 51,47% 97,31% 70,33% Debt to Equityt (%)

Gross Margin (%) 35,70% 19,28% 39,03% 49,39% 54,00% Gross Margin (%)

EBIT Margin (%) 5,79% 7,62% 12,12% 62,86% 131,66% EBIT Margin (%)

EBITDA Margin (%) 9,18% 9,27% 15,73% 58,94% 101,02% EBITDA Margin (%)

Net Profit Margin (%) 2,02% 4,45% 6,03% 73,68% 220,29% Net Profit Margin (%)

Days Receivable Turnover Days Receivable

(Hari) 58,35 32,08 45,84 69,99% 54,99% Turnover (Day)

Days Inventory Turnover Days Inventory Turnover

(Hari) 177,48 90,52 128,02 70,71% 51,00% (Day)

Days Payable Turnover Days Payable Turnover

(Hari) 82,53 25,38 55,12 46,05% 30,75% (Day)

Interest Coverage Interest Coverage (EBIT/

(EBIT/Interest) (Kali) 1,14 4,00 3,04 131,65% 350,18% Interest) (times)

Return on Invested Capital Return on Invested

(%) 2,54% 8,18% 7,01% 116,76% 322,65% Capital (%)

Return on Equity (%) 1,83% 11,11% 6,09% 182,37% 608,66% Return on Equity (%)

PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report 45

 Pembuka Laporan Manajemen Profil Perusahaan
Opening Management Report Company Profile

IKHTISAR POSISI KEUANGAN BIO FARMA SUMMARY OF THE CONSOLIDATED FINANCIAL

(ENTITAS INDUK) POSITION OF BIO FARMA (PARENT ENTITY)
Dalam Rp Juta In Rp Million

Ikhtisar Posisi Keuangan Entitas Summary of Parent Entity’s

2021 2020 2019
Induk Financial Position

Aset Lancar 15.427.002 7.944.511 2.523.919 Current Assets

Investasi pada Entitas Anak 12.479.821 12.479.821 - Investment in Subsidiaries

Aset Tetap 5.420.232 5.415.401 5.384.211 Fixed Assets

Aset Hak Guna 40.384 10.392 1.093 Right of Use Assets

Properti Investasi - - - Investment Properties

Aset Tak Berwujud 93.584 41.377 8.198 Intangible Assets

Aset Tidak Lancar Lainnya 1.024.413 155.151 22.978 Other Non-Current Assets

Total Aset 34.485.436 26.046.653 7.940.399 Total Assets

Liabilitas Jangka Pendek 10.507.005 4.198.555 967.100 Current Liabilities

Liabilitas Jangka Panjang 1.295.185 976.493 825.056 Non-Current Liabilities

Total Liabilitas 11.802.190 5.175.048 1.792.156 Total Liabilities

Total Ekuitas 22.683.246 20.871.605 6.148.243 Total Equity

Modal Kerja Bersih 4.919.997 3.636.321 1.556.819 Net Working Capital

IKHTISAR LAPORAN LABA RUGI BIO FARMA SUMMARY OF CONSOLIDATED STATEMENTS

(ENTITAS INDUK) OF PROFIT AND LOSS BIO FARMA (PARENT
ENTITY)
Dalam Rp Juta In Rp Million

Ikhtisar Laporan Laba Rugi Summary of Parent Entity’s

2021 2020 2019
Entitas Induk Financial Position

Pendapatan 30.320.454 2.790.043 2.542.592 Income

Laba Bruto 3.788.260 1.149.633 1.185.707 Gross Profit

Laba Usaha 2.514.404 456.918 569.859 Operating Profit

Laba Bersih Tahun Berjalan 1.916.575 355.166 355.940 Net Profit for the Year

Total Laba Komprehensif Tahun 1.888.361 317.819 348.371 Total Comprehensive Income
Berjalan for the Year

Laba yang Dapat Diatribusikan 1.888.361 317.819 348.371 Profit Attributable to Owners of
Kepada Pemilik Entitas Induk the Parent Entity

Laba yang Dapat Diatribusikan - - - Profit Attributable to Non-

Kepada Kepentingan Non Controlling Interests
Pengendali

Total 1.888.361 317.819 348.371 Total

46 PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report

 Analisis dan Pembahasan Manajemen atas Kinerja Perusahaan Tata Kelola Perusahaan
Management Discussion and Analysis regarding the Company’s Performance Good Corporate Governance

RASIO KEUANGAN BIO FARMA BIO FARMA (PARENT ENTITY) CONSOLIDATED

(ENTITAS INDUK) FINANCIAL RATIO

Rkap 2021
Real 2020 Real 2021 Parent Entity’s Financial
Rasio-rasio Keuangan Entitas Induk (Setelah
(Audited) (Audited) Ratios
Rups)

LIKUIDITAS LIQUIDITY

- Current Ratio 189,22% 314,83% 146,83% - Current Ratio

- Acid Test Ratio 82,26% 66,38% 80,56% - Acid Test Ratio

- Cash Ratio 76,07% 22,69% 61,20% - Cash Ratio

RENTABILITAS RENTABILITY

- Gross Profit Ratio 41,20% 45,57% 12,49% - Gross Profit Ratio

- Operating Margin Ratio 16,38% 19,04% 8,29% - Operating Margin Ratio

- Return on Equity 4,23% 6,03% 18,78% - Return on Equity

- Return on Investment 5,35% 11,64% 13,18% - Return on Investment

- Return on Invested Capital 1,75% 3,05% 7,29% - Return on Invested Capital

SOLVABILITAS SOLVENCY

- Total Debt to Total Equity 24,79% 11,01% 52,03% - Total Debt to Total Equity

MAIN DASHBOARD MAIN DASHBOARD

- EBITDA 661.546 933.244 2.789.258 - EBITDA

- CFO (1.046.351) 108.463 6.590.878 - CFO

- Interest Bearing DEBT 3.113.900 482.000 444.960 - Interest Bearing DEBT

- Debt to EBITDA 4,71 0,52 0,16 - Debt to EBITDA

PROFITABILITAS PROFITABILITY

- EBIT Margin 16,38% 19,04% 8,29% - EBIT Margin

- EBITDA Margin 23,71% 24,67% 9,20% - EBITDA Margin

- Net Profit Margin 12,73% 12,36% 6,32% - Net Profit Margin

WORKING CAPITAL WORKING CAPITAL

- Days Receivable Turnover 33,99 47,90 24,49 - Days Receivable Turnover

- Days Inventory Turnover 438,73 220,01 81,64 - Days Inventory Turnover

- Days Payable Turnover 59,88 44,47 20,45 - Days Payable Turnover

DEBT DEBT

- Interest Coverage (EBIT/Interest) 509,95% 771,54% 1423,72% - Interest Coverage (EBIT/Interest)

- DSCR 5,10 7,72 14,24 - DSCR

PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report 47

 Pembuka Laporan Manajemen Profil Perusahaan
Opening Management Report Company Profile

DIVIDEN DIVIDEND

Naik (Turun)
2019 2020 2021 % +(-) Increase
Uraian (Decrease) Description

3 4 5 6 (5/4) 7 (5-4)

Dividen 71.188 76.720 150.000 195,51% 73.280 Dividend

IKHTISAR KINERJA OPERASIONAL BIO FARMA OPERATIONAL PERFORMANCE

BIO FARMA OVERVIEW

Ikhtisar Kegiatan Produksi Vaksin dan Sera – Overview of Vaccine and Sera Production
Bio Farma (Entitas Induk Saja) Activities – Bio Farma (Parent Entity Only)

Satuan
Deskripsi 2019 2020 2021 Description
Unit

Produksi Vaksin Juta Dosis 1.309,20 2.242,54 1.343,11 Production of Viral

Virus Million Dose Vaccine

Pertumbuhan % (38,17)% 63,19% (40,11)% Growth

Produksi Vaksin Juta Dosis 455,08 424,07 200,71 Production of

Bakteri Million Dose Bacterial Vaccine

Pertumbuhan % (16,27)% (5,68)% (52,67)% Growth

Produksi Vaksin Juta Dosis 21,75 0,81 21,78 Production of

Kombinasi Million Dose Combination
Vaccine

Pertumbuhan % (43,97)% (96,28)% 2587,99% Growth

Produksi Sera & Juta Dosis 0,68 0,64 0,25 Production of Sera
Diagnostik Million Dose

Pertumbuhan % (29,51)% (6,63)% (60,04)% Growth

Produksi Bio Juta Dosis - 0,15 Bio similar Product

similar Million Dose

Pertumbuhan % 0.00% 0.00% Growth

Produksi Juta Dosis 44,21 59,06 110,52 Production of

Partnership Million Dose Partnership
Products

Pertumbuhan % (56,54)% 33,59% 87,11% Growth

Total Produksi Juta Dosis 1.830,92 2.727,12 1.676,53 Total Production

Million Dose

Pertumbuhan % (34,67)% 44,25% (38,52)% Growth

48 PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report

 Analisis dan Pembahasan Manajemen atas Kinerja Perusahaan Tata Kelola Perusahaan
Management Discussion and Analysis regarding the Company’s Performance Good Corporate Governance

Ikhtisar Kegiatan Produksi – Kimia Farma Overview of Production Activities – Kimia Farma

Satuan
Jenis Produk 2021 2020 2019 Type of Product
Unit

Obat-obatan & Diagnostik Drugs & Diagnostics

Tablet non Betalaktam Butir 1.244.903.862 1.119.073.710 2.094.198.026 Tablet
Item
Pertumbuhan % 11% (47%) 11% Growth
Tablet Salut Butir Item 399.734.958 266.017.970 663.422.015 Coated Tablet
Pertumbuhan % 50% (60%) (16%) Growth
Tablet ARV Butir Item 85.851.600 23.582.490 41.448.810 ARV Tablet
Pertumbuhan % 264% 43% (61%) Growth
Tablet Salut ARV Butir Item 54.196.830 50.054.130 5.737.650 ARV Coated Tablet
Pertumbuhan % 8% 772% (55%) Growth
Tablet Salut Herbal Butir Item 34.899.850 31.493.520 31.871.130 Herbal Coated Tablets
Pertumbuhan % 11% (1%) 28% Growth
Kapsul ARV Butir Item 729.000 722.580 65.732.400 ARV Capsule
Pertumbuhan % 1% (99%) - Growth
Kapsul Non Betalaktam Butir Item 137.605.540 168.201.610 11.976.186.780 Non-betalactam Capsule
Pertumbuhan % (18%) (99%) 64% Growth
Kapsul Lunak Butir Item 65.802.450 22.295.700 1.513.976.050 Kapsul Lunak
Pertumbuhan % 195% (99%) 8% Growth
Sirup Kering Non Botol Bottle 11.761 11.707 35.059 Non-betalactam Dry
Betalaktam Syrup
Pertumbuhan % - (67%) 53% Growth
Salep/Krim Tube 32.778.142 30.506.021 34.372.909 Ointment/Cream
Pertumbuhan % 7% (11%) (45%) Growth
Salep/Krim steril Tube - 630.580 8.277.979 Sterile Ointment/Cream
Pertumbuhan % (100%) (92%) (1%) Growth
Sirup/Suspensi Botol 712.978 0% 0% Syrup/Suspension
Pertumbuhan % (14% (53%) (39%) Growth
Ampul Injeksi Ampul 1.360.040 758.984 1.373.100 Ampoule Injection
Pertumbuhan % 79% (45%) (77%) Growth
Vial Injeksi Vial 3.998.295 - - Injection Vial
Pertumbuhan % - - - Growth
Cairan obat luar Botol Bottle 1.203.619 2.998.807 718.490 Liquid Medicine for
External Use
Pertumbuhan % (60%) 317% (52%) Growth
Cairan Obat Dalam Botol Bottle 848.408 1.610.611 1.756.520 Medicinal Liquid in Herbs
Herbal
Pertumbuhan % (47%) (8%) (17%) Growth
Cairan Obat Luar Herbal Botol 435.440 - 360.910 Herbal External Medicine
Liquid
Pertumbuhan % - (100%) (75%) Growth
Granul Herbal Sase - 467.800 288.750 Granul Herbal
Pertumbuhan % (100%) 62% (88%) Growth
Granul Pharma Sase 2.711.260 11.481.100 4.137.902.900 Granul Pharma
Pertumbuhan % (76%) (100%) 1565% Growth
Bedak Pcs 11.965.639 11.607.186 19.432.772 Powder
Pertumbuhan % 3% (40%) 38% Growth
Suppositoria Butir Item 2.137.770 906.520 14.869.150 Suppositoria
Pertumbuhan % 136% (94%) (72%) Growth

PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report 49

 Pembuka Laporan Manajemen Profil Perusahaan
Opening Management Report Company Profile

Satuan
Jenis Produk 2021 2020 2019 Type of Product
Unit

Kit Diagnostik In-Vitro Casset 47.520 126.674 - In Vitro Diagnostic Kit

Pertumbuhan % (62%) - - Growth
Kit Diagnostik In-Vitro Pcs - 282.452 944.129 Kit Diagnostik In-Vitro
(love Test) (love Test)

Pertumbuhan % (100%) (70%) 618% Growth

Produk KB Family Planning

Products

Pil KB Butir Item - - 326.480 Family Planning Pills

Pertumbuhan % - - (100%) Growth

Bahan Baku/Kimia Raw/Chemical Materials

Yodium Kg 29.700 31.150 33.400 Yodium

Pertumbuhan % (5%) (7%) (12%) Growth

Garam Yodium Kg 6.680 5.705 4.705 Garam Yodium

Pertumbuhan % 17% 21% 154% Growth

Minyak Lemak Fat Oil

Castor oil Kg 496.108 486.037 913.135 Castor oil

Pertumbuhan % 2% (47%) (14%) Growth

Edible Oil Kg 1.098.282 2.093.568 2.831.756 Edible Oil

Pertumbuhan % (48%) (26%) 56% Growth

Ikhtisar Kegiatan Produksi - INDOFARMA Production Activity Overview - Indofarma

Satuan
Jenis Produk 2021 2020 2019 Type of Product
Unit

Obat-obatan Drugs

Tablet Unit 552.843.558 585.675.712 698.745.349 Tablet

Pertumbuhan % (16,18%) (41,88%) Growth

Jumlah Produk Izin Edar 240 222 199 Total Products

Mendapatkan Marketing with Marketing
Nomor Izin Edar Authorization Authorization
(NIE) Number (NIE)

Pertumbuhan % 6,53% 15,03% Growth

Alat Kesehatan dan Produk Lainnya Medical Devices and Other Products

Volume Produksi Unit 5.000.632 1.387.051 159 Production

Volume

Pertumbuhan % (16,18%) (31,65%) Growth

Jumlah Produk Izin Edar 107 106 82 Total Products

Mendapatkan Marketing with Marketing
Nomor Izin Edar Authorization Authorization
(NIE) Number (NIE)

Pertumbuhan % 41,46% 41,38% Growth

50 PT Bio Farma (Persero) Laporan Tahunan 2021 Annual Report